File(s) not publicly available
Understanding cancer cell survival is key to patient survival
journal contribution
posted on 2023-06-10, 04:55 authored by Chris Fegan, Christopher PepperChristopher PepperThe outlook for individual patients with chronic lymphocytic leukaemia (CLL) has always been difficult to predict. This situation has led to the development of a plethora of prognostic markers, but nearly all studies have shown that 17p deletion consistently confers the worst outcome of all subtypes of CLL, with typical survival of 2–3 years as a result of low proportions of patients responding to primary chemo-immunotherapy and short progression-free survival. This cytogenetic lesion is quite rare in newly diagnosed patients (occurring in in 5–10% of such cases) but is much more prevalent in the relapsed and refractory setting (in up to 50% of patients).1
History
Publication status
- Published
Journal
The Lancet OncologyISSN
1470-2045Publisher
ElsevierExternal DOI
Issue
2Volume
16Page range
122-124Event location
EnglandDepartment affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes